Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: A systematic review

Abderrahim Oussalah, Silvio Danese, Laurent Peyrin-Biroulet

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on the long-term efficacy and safety of anti-TNF therapy in IBD beyond 1 year. We searched Medline, the Cochrane Library, Embase, and Ovid Medliner for relevant studies. Infliximab, adalimumab and certolizumab are effective in maintaining clinical remission in luminal Crohn's disease. Infliximab and adalimumab are also effective in maintaining long-term fistula closure in Crohn's disease. Only infliximab has been evaluated in UC in the long term, with similar data on its effectiveness than in CD. In addition to the maintenance of clinical remission, TNF antagonists have the ability to maintain long-term mucosal healing, resulting in a reduced risk of surgery. With 2010 on the horizon, we have no good reasons to stop anti-TNF therapy in IBD patients because of its efficacy in maintaining remission and a risk-benefit ratio that remains in its favor. It is now clear that patients in deep remission, comprising clinical, biological, and endoscopic remission, are at lower risk of relapse after withdrawal of anti-TNF therapy.

Original languageEnglish
Pages (from-to)156-175
Number of pages20
JournalCurrent Drug Targets
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Pediatrics
Inflammatory Bowel Diseases
Tumor Necrosis Factor-alpha
Crohn Disease
Ulcerative Colitis
Immunologic Factors
Therapeutics
Libraries
Fistula
Adrenal Cortex Hormones
Refractory materials
Surgery
Odds Ratio
Maintenance
Safety
Recurrence
Infliximab

Keywords

  • Adalimumab
  • Crohn's disease
  • Infliximab
  • Long-term outcome
  • Mucosal healing
  • Ulcerative colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases : A systematic review. / Oussalah, Abderrahim; Danese, Silvio; Peyrin-Biroulet, Laurent.

In: Current Drug Targets, Vol. 11, No. 2, 02.2010, p. 156-175.

Research output: Contribution to journalArticle

@article{b530808dc6994fceaefa59e3497579c5,
title = "Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: A systematic review",
abstract = "The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on the long-term efficacy and safety of anti-TNF therapy in IBD beyond 1 year. We searched Medline, the Cochrane Library, Embase, and Ovid Medliner for relevant studies. Infliximab, adalimumab and certolizumab are effective in maintaining clinical remission in luminal Crohn's disease. Infliximab and adalimumab are also effective in maintaining long-term fistula closure in Crohn's disease. Only infliximab has been evaluated in UC in the long term, with similar data on its effectiveness than in CD. In addition to the maintenance of clinical remission, TNF antagonists have the ability to maintain long-term mucosal healing, resulting in a reduced risk of surgery. With 2010 on the horizon, we have no good reasons to stop anti-TNF therapy in IBD patients because of its efficacy in maintaining remission and a risk-benefit ratio that remains in its favor. It is now clear that patients in deep remission, comprising clinical, biological, and endoscopic remission, are at lower risk of relapse after withdrawal of anti-TNF therapy.",
keywords = "Adalimumab, Crohn's disease, Infliximab, Long-term outcome, Mucosal healing, Ulcerative colitis",
author = "Abderrahim Oussalah and Silvio Danese and Laurent Peyrin-Biroulet",
year = "2010",
month = "2",
doi = "10.2174/138945010790309939",
language = "English",
volume = "11",
pages = "156--175",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases

T2 - A systematic review

AU - Oussalah, Abderrahim

AU - Danese, Silvio

AU - Peyrin-Biroulet, Laurent

PY - 2010/2

Y1 - 2010/2

N2 - The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on the long-term efficacy and safety of anti-TNF therapy in IBD beyond 1 year. We searched Medline, the Cochrane Library, Embase, and Ovid Medliner for relevant studies. Infliximab, adalimumab and certolizumab are effective in maintaining clinical remission in luminal Crohn's disease. Infliximab and adalimumab are also effective in maintaining long-term fistula closure in Crohn's disease. Only infliximab has been evaluated in UC in the long term, with similar data on its effectiveness than in CD. In addition to the maintenance of clinical remission, TNF antagonists have the ability to maintain long-term mucosal healing, resulting in a reduced risk of surgery. With 2010 on the horizon, we have no good reasons to stop anti-TNF therapy in IBD patients because of its efficacy in maintaining remission and a risk-benefit ratio that remains in its favor. It is now clear that patients in deep remission, comprising clinical, biological, and endoscopic remission, are at lower risk of relapse after withdrawal of anti-TNF therapy.

AB - The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC), refractory to conventional medications (corticosteroids, immunomodulators). This review summarizes current data on the long-term efficacy and safety of anti-TNF therapy in IBD beyond 1 year. We searched Medline, the Cochrane Library, Embase, and Ovid Medliner for relevant studies. Infliximab, adalimumab and certolizumab are effective in maintaining clinical remission in luminal Crohn's disease. Infliximab and adalimumab are also effective in maintaining long-term fistula closure in Crohn's disease. Only infliximab has been evaluated in UC in the long term, with similar data on its effectiveness than in CD. In addition to the maintenance of clinical remission, TNF antagonists have the ability to maintain long-term mucosal healing, resulting in a reduced risk of surgery. With 2010 on the horizon, we have no good reasons to stop anti-TNF therapy in IBD patients because of its efficacy in maintaining remission and a risk-benefit ratio that remains in its favor. It is now clear that patients in deep remission, comprising clinical, biological, and endoscopic remission, are at lower risk of relapse after withdrawal of anti-TNF therapy.

KW - Adalimumab

KW - Crohn's disease

KW - Infliximab

KW - Long-term outcome

KW - Mucosal healing

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=77950791967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950791967&partnerID=8YFLogxK

U2 - 10.2174/138945010790309939

DO - 10.2174/138945010790309939

M3 - Article

C2 - 20210765

AN - SCOPUS:77950791967

VL - 11

SP - 156

EP - 175

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -